Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3293

Latigo collects $150M to get non-opioid data to compete with Vertex in acute pain

$
0
0
Latigo Biotherapeutics thinks it can one-up Vertex Pharmaceuticals' recently approved Journavx, which ignited the non-opioid landscape for treating pain. The Los Angeles-area biotech is testing a similar type of small molecule, called ...

Viewing all articles
Browse latest Browse all 3293

Trending Articles